GlassScriptPhysician profile
Catherine B Johnson
NPI 1952424129
$952.13
in general payments reported to CMS, 2019-2025
18 companies · $195 in 2025
The $195 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $60.30 · 2022: $196 · 2023: $310 · 2024: $191 · 2025: $195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $696.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $696.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $197.71 | 2022-2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $185.66 | 2022-2024 | |
| Glaukos Corporation | $92.75 | 2023 | |
| Supernus Pharmaceuticals, INC. | $66.28 | 2022-2023 | Qelbree |
| Collegium Pharmaceutical, INC. | $59.43 | 2025 | Jornay Pm |
| Sanofi-Aventis U.S. LLC | $40.69 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $38.00 | 2022-2023 | Crysvita |
| Cranial Technologies, INC | $37.12 | 2023-2024 | Doc Band |
| Sanofi Pasteur INC. | $33.64 | 2025 | |
| Merck Sharp & Dohme LLC | $31.88 | 2024-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Sobi, INC | $30.55 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $28.96 | 2025 | Zoryve |
| Pfizer INC. | $27.52 | 2021-2023 | |
| Boston Scientific Corporation | $21.48 | 2021 | |
| Seqirus USA INC | $17.08 | 2025 | Flucelvax |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $15.45 | 2024 | Hillrom - Spot Vision Screener |
| Takeda Pharmaceuticals U.S.A., INC. | $14.24 | 2021 | |
| Glaxosmithkline, LLC. | $13.69 | 2023 | Menveo, Bexsero |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.